Prelude Therapeutics Investor Relations Material
Latest events
Study Update
Prelude Therapeutics
Q1 2025
6 May, 2025
Q4 2024
10 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Prelude Therapeutics Inc
Access all reports
Prelude Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, small molecule therapies targeting key drivers of cancer cell growth and resistance. Leveraging its expertise in cancer biology, medicinal chemistry, and drug development, Prelude Therapeutics is committed to advancing a pipeline of innovative treatments aimed at addressing the complex challenges of cancer treatment. The company is headquartered in Wilmington, Delaware, and its shares are listed on the Nasdaq.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
PRLD
Country
🇺🇸 United States